CiRNAseq is a newly developed and proprietary technology with the following key features:

• high throughput through barcode technology (hundreds of samples analyzed in one assay)

• highly multiplexed (hundreds of expressed genes of interest analyzed in each sample)

• highly specific (sequence based)

• quantitative (result is not biased by preferential PCR amplification)

• adjustable (just expand for quantitative measurement of other gene transcripts of interest

With ciRNAseq, Predica Diagnostics detects aberrant biological pathways, including overexpression of human and viral genes, mutations in expressed genes and alternatively spliced messenger RNAs (mRNA). This information can be used to find a matching cancer drug. The use of ciRNAseq for tissue and cell analysis is protected by patent “RNA profiling for individualized diet and treatment advice” with number PCT/EP2018/055548 filed on March 7, 2017 in key geographic areas.

Learn more about ciRNAseq by exploring our scientific publications